Career Adaptability Mediates the Effect of Trait Emotional Intelligence on Academic Engagement

En el presente estudio se comprueba el papel mediador de la adaptabilidad a la carrera en la relación existente entre la inteligencia emocional (IE) rasgo y el compromiso académico. La muestra comprende 590 estudiantes universitarios españoles con una edad media de 21.66 años. En los resultados se confirman las relaciones positivas entre la IE rasgo, la adaptabilidad a la carrera y el compromiso académico. Un hallazgo clave es la confirmación del papel mediador de la adaptabilidad a la carrera, modelo de mediación total, en la relación entre la IE rasgo y el compromiso académico. Este estudio aporta una valiosa contribución científica que permite una mejor y más precisa aclaración de los vínculos entre la IE, la adaptabilidad profesional y el compromiso académico. La discusión se centra en las cuestiones relativas a la relación entre estas variables y la posibilidad de desarrollar intervenciones para mejorar la adaptabilidad profesional y el compromiso académico entre estudiantes universitarios. // The present study tested the mediating role of career adaptability on the existing relation between trait emotional intelligence (EI) and academic engagement. The sample consisted of 590 Spanish university students with a mean age of 21.66 years. The results confirmed the positive relations of trait EI with career adaptability, as well as with academic engagement. A key finding concerns the confirmation of the mediating role of career adaptability on the relation between trait EI and academic engagement, supporting a model of total mediation. In confirming the existence of total mediation, this study makes a new and valuable contribution that allows for better and more precise clarification of the links between trait EI, career adaptability, and academic engagement. The discussion focuses on issues concerning the relation between these variables and the possibility of developing interventions to improve career adaptability and academic engagement in undergraduate populations

Interrelación de laboratorios de control y laboratorios de investigación en España para la armonización de metodologías de determinación de toxinas paralizantes

XII Congreso Nacional de Agricultura, Madrid 24-26 de noviembre de 2009Marketing of cultured and harvested shellfish is linked to monitoring programs for granting food safety. Its complexity requires constant cooperation between research and monitoring laboratories in order to improve sampling and analysing performances, achieve legal requirements, etc. for increasing consumer’s health protection but not reducing producer’s benefits. The JACUMAR project «Comparison of methodologies for the evaluation of Paralytic Shellfish Poisoning (PSP) toxins in bivalves. Application for aquaculture in Spain» groups research and monitoring laboratories from Galicia, Andalucía and Cataluña. Efforts are focused on detection and quantification of PSP toxins, searching an analytical method able to fulfil technical and management requirementsEste proyecto está financiado por la Junta Asesora de Cultivos Marinos (JACUMAR), y los programas de control por los gobiernos autónomos de Galicia, Andalucía y CataluñaN

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Sensitivity of the Cherenkov Telescope Array for probing cosmology and fundamental physics with gamma-ray propagation

The Cherenkov Telescope Array (CTA), the new-generation ground-based observatory for γ astronomy, provides unique capabilities to address significant open questions in astrophysics, cosmology, and fundamental physics. We study some of the salient areas of γ cosmology that can be explored as part of the Key Science Projects of CTA, through simulated observations of active galactic nuclei (AGN) and of their relativistic jets. Observations of AGN with CTA will enable a measurement of γ absorption on the extragalactic background light with a statistical uncertainty below 15% up to a redshift z=2 and to constrain or detect γ halos up to intergalactic-magnetic-field strengths of at least 0.3 pG . Extragalactic observations with CTA also show promising potential to probe physics beyond the Standard Model. The best limits on Lorentz invariance violation from γ astronomy will be improved by a factor of at least two to three. CTA will also probe the parameter space in which axion-like particles could constitute a significant fraction, if not all, of dark matter. We conclude on the synergies between CTA and other upcoming facilities that will foster the growth of γ cosmology.</p

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

BACKGROUND: No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis. METHODS: In INFORMS, a multicentre, double-blind, placebo-controlled parallel-group study, patients with primary progressive multiple sclerosis recruited across 148 centres in 18 countries were randomly allocated (1:1) with computer-generated blocks to receive oral fingolimod or placebo for at least 36 months and a maximum of 5 years. Patients were initially assigned to fingolimod 1·25 mg per day or placebo (cohort 1); however, after a protocol amendment on Nov 19, 2009, patients were switched in a masked manner to fingolimod 0·5 mg, whereas those on placebo continued on matching placebo. From then onwards, patients were assigned to receive fingolimod 0·5 mg/day or placebo (cohort 2). Key inclusion criteria were age 25-65 years, clinical diagnosis of primary progressive multiple sclerosis, 1 year or more of disease progression, and two of the following criteria: positive brain MRI; positive spinal cord MRI; or positive cerebrospinal fluid. Additional eligibility criteria included disease duration of 2-10 years and objective evidence of disability progression in the previous 2 years. Patients and study investigators were masked to group assignment. We used a novel primary composite endpoint based on change from baseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-month confirmed disability progression in study participants treated for at least 3 years. All randomised patients took at least one dose of study drug. The primary efficacy analysis included all patients in cohort 2 and those assigned to placebo in cohort 1. The safety analysis included all patients in cohorts 1 and 2. This study is registered with ClinicalTrials.gov, number NCT00731692. The study is now closed. FINDINGS: 970 patients were randomly assigned between Sept 3, 2008, and Aug 30, 2011 (147 to fingolimod 1·25 mg and 133 to placebo in cohort 1; 336 to fingolimod 0·5 mg and 354 to placebo in cohort 2). The efficacy analysis set (n=823) consisted of 336 patients randomly allocated to fingolimod 0·5 mg and 487 to placebo. Baseline characteristics were similar across groups and representative of a primary progressive multiple sclerosis population (48% women, mean age 48·5 years [SD 8·4], mean EDSS 4·67 [SD 1·03], 87% free of gadolinium-enhancing lesions). By end of study, 3-month confirmed disability progression had occurred in 232 and 338 patients in the fingolimod and placebo groups, respectively, resulting in Kaplan-Meier estimates of 77·2% (95% CI 71·87-82·51) of patients in the fingolimod group versus 80·3% (73·31-87·25) of patients in the placebo group (risk reduction 5·05%; hazard ratio 0·95, 95% CI 0·80-1·12; p=0·544). Safety results were generally consistent with those of studies of fingolimod in patients with relapse-onset multiple sclerosis. Lymphopenia occurred in 19 (6%) patients in the fingolimod group versus none in the placebo group, bradycardia in five (1%) versus one (<1%), and first-degree atrioventricular block in three (1%) versus six (1%). Serious adverse events occurred in 84 (25%) patients in the fingolimod group and 117 (24%) in the placebo group, including macular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%). INTERPRETATION: The anti-inflammatory effects of fingolimod did not slow disease progression in primary progressive multiple sclerosis. Therapeutic strategies for primary progressive multiple sclerosis might need different approaches to those used for relapse-onset multiple sclerosis

CTA sensitivity for probing cosmology and fundamental physics with gamma rays

The Cherenkov Telescopic Array (CTA), the next-generation ground-based gamma-ray observatory, will have unprecedented sensitivity, providing answers to open questions in gamma-ray cosmology and fundamental physics. Using simulations of active galactic nuclei observations foreseen in the CTA Key Science Program, we find that CTA will measure gamma-ray absorption on the extragalactic background light with a statistical error below 15% up to the redshift of 2 and detect or establish limits on gamma halos induced by the intergalactic magnetic field of at least 0.3 pG. Extragalactic observations using CTA also demonstrate the potential for testing physics beyond the Standard Model. The best state-of-the-art constraints on the Lorentz invariance violation from astronomical gamma-ray observations will be improved at least two- to threefold. CTA will also probe the parameter space where axion-like particles can represent a significant proportion – if not all – of dark matter. Joint multiwavelength and multimessenger observations, carried out together with other future observatories, will further foster the growth of gamma-ray cosmology